Free Newsletter
FDA selects flu strains for next round of vaccines
The FDA has come up with a lineup of three all-new flu strains for this year's vaccine recipe. Typically, only one or two strains are changed, but health officials felt that following last season's ineffective vaccine jab a new approach was called for.
It's not easy getting the strains right. Most vaccines are consistently effective against their targets. But the steadily changing nature of influenza makes it a tough target to hit. Inevitably, there's always a guessing game about which strains will be circulating during an upcoming flu season.
This season's list of manufacturers and approved vaccines (by way of the Washington Post): CSL Limited, Afluria; GlaxoSmithKline Biologicals, Fluarix; ID Biomedical, FluLaval; MedImmune Vaccines, FluMist; Novartis Vaccines and Diagnostics, Fluvirin; and Sanofi Pasteur, Fluzone.
- read the story from the Washington Post
Related Articles:
Flu jab missing the mark in seasonal campaign
Vaccines ineffective in seasonal flu campaign
Breakthrough reported in flu vaccine research
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: